share_log

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $217

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $217

瑞银维持泰尼特买入评级,将目标股价提高至217美元
Benzinga ·  10/30 10:12  · 评级/大行评级

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $197 to $217.

瑞银分析师A.J. Rice维持Tenet Healthcare(纽约证券交易所代码:THC)的买入,并将目标股价从197美元上调至217美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发